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• Pancreatic neuroendocrine tumors (PNETs) are 
very rare and represent about 1–2% of all 
pancreatic tumors.  
• Non-functional PNETs (NF-PNETs) represent 
approximately 85% of all PNETs. They are 
mostly found incidentally at an advanced stage 
because patients are asymptomatic and the 
tumors do not secrete hormones that would 
manifest with symptoms. 
• More than 95 percent of the pancreatic 
neoplasms arise from the exocrine component 
of the pancreas. Neoplasms arising from the 
endocrine pancreas are neuroendocrine 
tumors (NETs). 
• PNETs, also known as islet cell tumors, 
originate in the islets of Langerhans. PNETs are 
rare neoplasms of the pancreas, with an 
incidence of 1/100,000/year and account for 
about 1-2% of all pancreatic neoplasms [2].  
• Computed tomography (CT) is the imaging 
modality of choice, but other diagnostic 
imaging tools need to be investigated for 
earlier detection of this insidious and fatal 
disease.  
• Surgical  treatment is currently preferred, but 
only palliative chemotherapy and radiation is 
currently available for advanced disease.  
• We report a case of 32-yr-old female  who 
initially presented with increasing abdominal 
girth, decreased mobility, and lower extremity 
swelling up to the hip and she was incidentally 
found to have a widely metastatic 
intermediate grade NF-PNET stage IV T2N0M1 
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as G2 tumors, when they express 2-20 
mitoses/10 HPF and 3-20% Ki-67, whereas 
neuroendocrine carcinomas (NECs) usually 
belong to G3 category, with >20 mitoses/10 HPF 
and >20% Ki-67 index [1].  
• The patient had Ki 67 of 40%.  
• Potential risk factors for PNETs include 
diabetes, smoking, a previous history of 
chronic pancreatitis, and genetic factors 
(hereditary endocrinopathies, including 
multiple endocrine neoplasia types I) [2], 
However the patient had no risk factors for 
this disease.  
• Clinical management involves a 
multidisciplinary approach, but surgery 
remains the only curative therapy for early-
stage disease.  
• Radical  surgery for pancreatic NET offers a 5-
year survival rate of 45-92%, highlighting the 
importance of accurate diagnosis  and 
appropriate referral of patients for surgery [3]. 
 
 
• Because of its rarity, randomized controlled 
studies have not been done and current 
treatment recommendations are based 
primarily on case series and individual 
treatment approaches  [4].  
• Further research is under way on newer, 
investigational drugs.  
1Rowan University SOM, Department of Medicine, Stratford, NJ, 2Comprehensive Cancer and Hematology Specialists, P.C, Voorhees, NJ 
 
 
• This is a case of a young female  who 
underwent a computed tomography of the 
abdomen and pelvis (CT) in 2016  that showed 
a massively enlarged liver with diffuse 
metastases and her largest lesion measured 
5.8x4.9cm.  
• The patient  also had a 3.5x3.6 cm pancreatic 
tail mass as well as a 10.3x11 cm mass in her 







• The patient underwent a core biopsy of her 
liver on 01/28/2016 and her pathology 
showed a metastatic neuroendocrine tumor 
with Ki 67 of 40% and a mitotic rate of 10 per 
10 HPF.  
• Treatment with capecitabine and 
temozolomide began shortly after.  
• A repeat CT of the abdomen and pelvis on 
06/24/2016 showed significant decrease in 
her pancreatic mass and liver metastases.  
• Chromogranin A level had decreased from 
5800 to 35 ng/dL. She completed 6 cycles of 
chemotherapy and then had an exploratory 
laparotomy, lysis  of adhesions, and bilateral 
oopherectomy with the gynecology service. 
• The patient was  found to have metastatic 
disease with peritoneal deposits to her 
sigmoid colon and her peritoneum. Her 
treatment was  changed to octreotide and 
everolimus postoperatively until 
 
the MRI of her abdomen in  mid 2017 showed 
progression of  liver metastases.  
• The patient  was then changed to 
doxorubicin, 5-fluorouracil (5-FU), and 
streptozocin.  
• Repeat imaging showed improvement of her 
metastases to the liver. 
• The patient  received four cycles of treatment 
and she then received Y90 to her liver that 
completed in early 2018.  
• A repeat MRI of the abdomen showed stable 
disease in her liver.  
• A bone scan shortly after showed multiple 
bone lesions and she was having significant 
bone pain. She received one cycle of 
platinum and etoposide and she felt that her 
bone pain was improving.  
• A gallium 68 PET CT was recommended to 
clarify if the patient had an overexpression of 
somatostatin receptors and this would be 
more consistent with a slower growing NET. 
The patient would then receive treatment 
with Peptide Receptor Radionuclide Therapy 
(PRRT).  
• The patient  was diagnosed with widely 
metastatic intermediate grade NF-PNET stage 
IV T2N0M1 to the liver, peritoneum, bones, 




• According to the World Health Organization 
(WHO) classification, three classes of NETs 
can be identified based on histology and 
pathology: well-differentiated NETs can be 
classified as G1 tumors, when they express 
<2 mitoses/10 HPF and ≤2% Ki-67 index;  
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